237 related articles for article (PubMed ID: 23720056)
1. TR3 modulates platinum resistance in ovarian cancer.
Wilson AJ; Liu AY; Roland J; Adebayo OB; Fletcher SA; Slaughter JC; Saskowski J; Crispens MA; Jones HW; James S; Fadare O; Khabele D
Cancer Res; 2013 Aug; 73(15):4758-69. PubMed ID: 23720056
[TBL] [Abstract][Full Text] [Related]
2. Induction of apoptosis in PA-1 ovarian cancer cells by vitamin K2 is associated with an increase in the level of TR3/Nur77 and its accumulation in mitochondria and nuclei.
Sibayama-Imazu T; Fujisawa Y; Masuda Y; Aiuchi T; Nakajo S; Itabe H; Nakaya K
J Cancer Res Clin Oncol; 2008 Jul; 134(7):803-12. PubMed ID: 18202854
[TBL] [Abstract][Full Text] [Related]
3. Activation of nuclear TR3 (NR4A1) by a diindolylmethane analog induces apoptosis and proapoptotic genes in pancreatic cancer cells and tumors.
Yoon K; Lee SO; Cho SD; Kim K; Khan S; Safe S
Carcinogenesis; 2011 Jun; 32(6):836-42. PubMed ID: 21362629
[TBL] [Abstract][Full Text] [Related]
4. Orphan receptor TR3 participates in cisplatin-induced apoptosis via Chk2 phosphorylation to repress intestinal tumorigenesis.
Yao LM; He JP; Chen HZ; Wang Y; Wang WJ; Wu R; Yu CD; Wu Q
Carcinogenesis; 2012 Feb; 33(2):301-11. PubMed ID: 22159226
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of the orphan nuclear receptor TR3/Nur77 inhibits pancreatic cancer cell and tumor growth.
Lee SO; Abdelrahim M; Yoon K; Chintharlapalli S; Papineni S; Kim K; Wang H; Safe S
Cancer Res; 2010 Sep; 70(17):6824-36. PubMed ID: 20660371
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
7. ERα-targeted therapy in ovarian cancer cells by a novel estradiol-platinum(II) hybrid.
Brasseur K; Leblanc V; Fabi F; Parent S; Descôteaux C; Bérubé G; Asselin E
Endocrinology; 2013 Jul; 154(7):2281-95. PubMed ID: 23677930
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.
Muñoz-Galván S; Felipe-Abrio B; Verdugo-Sivianes EM; Perez M; Jiménez-García MP; Suarez-Martinez E; Estevez-Garcia P; Carnero A
Mol Cancer; 2020 Jan; 19(1):7. PubMed ID: 31926547
[TBL] [Abstract][Full Text] [Related]
9. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro.
Hahne JC; Honig A; Meyer SR; Gambaryan S; Walter U; Wischhusen J; Häussler SF; Segerer SE; Fujita N; Dietl J; Engel JB
Oncol Rep; 2012 Dec; 28(6):2023-8. PubMed ID: 22992944
[TBL] [Abstract][Full Text] [Related]
11. DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance.
Stronach EA; Chen M; Maginn EN; Agarwal R; Mills GB; Wasan H; Gabra H
Neoplasia; 2011 Nov; 13(11):1069-80. PubMed ID: 22131882
[TBL] [Abstract][Full Text] [Related]
12. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
[TBL] [Abstract][Full Text] [Related]
13. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Targeting of ATP7B in Ovarian Carcinoma.
Mangala LS; Zuzel V; Schmandt R; Leshane ES; Halder JB; Armaiz-Pena GN; Spannuth WA; Tanaka T; Shahzad MM; Lin YG; Nick AM; Danes CG; Lee JW; Jennings NB; Vivas-Mejia PE; Wolf JK; Coleman RL; Siddik ZH; Lopez-Berestein G; Lutsenko S; Sood AK
Clin Cancer Res; 2009 Jun; 15(11):3770-80. PubMed ID: 19470734
[TBL] [Abstract][Full Text] [Related]
15. Orphan nuclear receptor TR3/Nur77 biologics inhibit tumor growth by targeting angiogenesis and tumor cells.
Chen C; Li Y; Hou S; Bourbon PM; Qin L; Zhao K; Ye T; Zhao D; Zeng H
Microvasc Res; 2020 Mar; 128():103934. PubMed ID: 31654655
[TBL] [Abstract][Full Text] [Related]
16. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
17. Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer.
Xia X; Ma Q; Li X; Ji T; Chen P; Xu H; Li K; Fang Y; Weng D; Weng Y; Liao S; Han Z; Liu R; Zhu T; Wang S; Xu G; Meng L; Zhou J; Ma D
BMC Cancer; 2011 Sep; 11():399. PubMed ID: 21933447
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional epigenetic regulation of Fkbp1/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer.
Soto JA; Rodríguez-Antolín C; Vera O; Pernía O; Esteban-Rodríguez I; Dolores Diestro M; Benitez J; Sánchez-Cabo F; Alvarez R; De Castro J; Ibanez de Cáceres I
Clin Epigenetics; 2021 Aug; 13(1):167. PubMed ID: 34454589
[TBL] [Abstract][Full Text] [Related]
19. TR3 is involved in hypoxia-induced apoptosis resistance in lung cancer cells downstream of HIF-1α.
Wohlkoenig C; Leithner K; Olschewski A; Olschewski H; Hrzenjak A
Lung Cancer; 2017 Sep; 111():15-22. PubMed ID: 28838387
[TBL] [Abstract][Full Text] [Related]
20. p62/SQSTM1 as an oncotarget mediates cisplatin resistance through activating RIP1-NF-κB pathway in human ovarian cancer cells.
Yan XY; Zhang Y; Zhang JJ; Zhang LC; Liu YN; Wu Y; Xue YN; Lu SY; Su J; Sun LK
Cancer Sci; 2017 Jul; 108(7):1405-1413. PubMed ID: 28498503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
